Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
Stock Information for Avalo Therapeutics Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About Avalo Therapeutics Inc.
Origin Materials and Avantium to Accelerate the Mass Production of FDCA and PEF for Advanced Chemicals and Plastics
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants